Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue

Medical and Pediatric Oncology

Volumn 26, Issue 2, 1996, Pages 95-100

  Freilich, Ronnie J ^a   Kraus, Dennis H ^a   Budnick, Amy S ^a   Bayer, Lisa A ^a   Finlay, Jonathan L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

brain tumors; ototoxicity; platinum drugs

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; VINCRISTINE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; OTOTOXICITY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUDIOMETRY; AUDITORY THRESHOLD; BONE MARROW TRANSPLANTATION; BRAIN NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; HEARING LOSS, HIGH-FREQUENCY; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030045973     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199602)26:2<95::AID-MPO5>3.0.CO;2-P     Document Type: Article

References (36)

1. Duffner PK, Cohen ME, Myers MH, Heise HW: Survival of children with brain tumors: SEER program, 1973-1980. Neurology 36:597-601, 1986.
2. Duffner PK, Cohen ME: The long-term effects of central nervous system therapy on children with brain tumors. Neurologic Clinics 9:479-495, 1991.
3. Chin H, Maruyama Y: Age at treatment and long term performance results in medulloblastoma. Cancer 53:1952-1958, 1984.
4. Puccetti D, Grovas A, Garvin J, Weinblatt M, Sadhev I, Tugal O, Jayabose S, Halpern S, Drachtman R, Goldman S, Odom L, Bayer LA, McElwain M, Dunkel I, Thompson SJ, Gillio A, Allen JC, Finlay JL: Feasibility of a dose-intensive induction chemotherapy regimen followed by consolidation with high-dose chemotherapy and autologous marrow rescue (the "Head Start" protocol) for children less than six years of age with newly-diagnosed malignant brain tumors. J Fed Neurosurg 21:164, 1994.
5. Waterhouse DM, Reynolds RK, Natale RB: Combined carboplatin and cisplatin. Limited prospects for dose intensification. Cancer 71:4060-4066, 1993.
6. Dittrich C, Sevelda P, Baur M, Marth C, Hudec M, Vavra N, Grunt T, Fazeny B, Salzer H: In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer 71:3082-3090, 1993.
7. Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M: Clinical status of carbopiatin. Oncology 1:61-69, 1987.
8. Reed E: Platinum analogues. In DeVita VT, Hellman S, Rosenberg SA (eds), "Cancer: Principles and Practice of Oncology." Philadelphia: Lippincott, 1993, pp. 390-400.
9. Schweitzer VG: Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26:759-789, 1993.
10. Stadnicki SW, Fleischman RW, Schaeppi U, Merriam P: Cisdichlorodiammineplatinum (II) (NSC-119875): Hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 59:467-480. 1975.
11. Kohn S, Fradis M, Pratt H, Zidan J, Podoshin L, Robinson E, Nir I: Cisplatinum Ototoxicity in guinea pigs with special reference to toxic effects in the stria vascularis. Laryngoscope 98:865-871, 1988.
12. Granowetter L, Rosenstock JG, Packer RJ: Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neuro-Oncol 1:293-297, 1983.
13. Sexauer CL, Khan A, Burger PC, Krischer JP, van Eys J, Vats T, Ragab AH: Cisplatin in recurrent pediatric brain tumors. Cancer 56:1497-1501, 1985.
14. Walker DA, Pillow J, Waters KD, Keir E: Enhanced cisplatin ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol 17: 48-52, 1989.
15. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MHN: Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 66:19-23, 1982.
16. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY: Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98:858-864, 1988.
17. Laurell G, Jungnelius U: High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100:724-734, 1990.
18. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991.
19. Weatherly RA, Owens JJ, Catlin FI, Mahoney DH: Cis-platinum ototoxicity in children. Laryngoscope 101:917-924, 1991.
20. Helson L, Okonkwo E, Anton L, Cvitkovic E: Cis-platinum ototoxicity. Clin Toxicol 13:469-478, 1978.
21. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J; Ototoxicity due to cis-diamminodichloroplatinum in the treatment of ovarian cancer: Influence of dosage and schedule of administration. Ear Hear 12:91-102, 1991.
22. Pasic TR, Dobie RA: Cis-platinum ototoxicity in children. Laryngoscope 101:985-991, 1991.
23. Myers S, Blakley BW, Schwan S, Rintelmann WF, Mathog RH: The "plateau effect" of cis-platinum induced hearing loss. Otolaryngol Head Neck Surg 104:122-127, 1991.
24. Saito T, Saito H, Saito K, Wakui S, Manabe Y, Tsuda G: Ototoxicity of carboplatin in guinea pigs. Auris, Nasus, Larynx 16:13-21, 1989.
25. Taudy M, Syka J, Popelar J, Ulehlova L: Carboplatin andcisplatin ototoxicity in guinea pigs. Audiology 31:293-299, 1992.
26. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD: Carboplatin in childhood brain tumors: A Children's Cancer Study Group phase II trial. Cancer 66:2465-2469, 1990.
27. Kennedy ICS, Fitzharris BM, Colls BM, Atkinson CH: Carboplatin is ototoxic. Cancer Chemother Pharmacol 26:232-234, 1990.
28. Sadowitz PD, Dubowy RL, Ragab A, Sanders JM, Vats T, Parmley R, Land V, Buchanan G, Vietti T: Phase I trial of etoposide and continuous infusion carboplatin (CBDCA) in children with refractory acute leukemia. Proc AACR 33:1253, 1992.
29. Zamboglou N, Achterrath W, Schnabel T, Lenaz L, Kolotas C, Schmitt G: Simultaneous radiotherapy and chemotherapy with carboplatin in inoperable squamous cell carcinoma of the head and neck: A phase II study. Cancer Invest 10:349-355, 1992.
30. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661, 1989.
31. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE. Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989.
32. van der Hulst RJAM, Dreschler WA, Urbanus NAM: High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Ottol Rhinol Laryngol 97:133-137, 1988.
33. Rebollo J, Henriquez I, Martin Algarra S, Fernandez Hidalgo O, Munoz-Galindo L, Vieitez JM: High dose combination of carboplatin (CBDCA) and etoposide (VP-16) followed by peripheral blood stem cell (PBSC) transplantation in the treatment of ovarian carcinoma. Proc AACR 32:1025, 1991.
34. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558-563, 1992.
35. Elfenbein G, Fields K, Zorsky P, Hiemenz J, Janssen W, Perkins J, Gonzalez J, Green S, Oelslager P, Kronish L, Machak M: Ifosfamide, carbopiatin and etoposide (ICE) with autologous stem cell rescue (ASCR); toxicities. Proc ASCO 11:187, 1992.
36. Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S: Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 9:1793-800, 1991.